SCRI-CAR19v3

Phase 1Biologic

SSeattle Children's Hospital

SCRI-CAR19v3 is one of 6 biologic programs targeting Autoimmunity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AutoimmunityRecruiting

AutoimmunityPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Autoimmunity

#DrugCompanyPhaseTrials

Skyrizi

AbbVie

Approved

1 2

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 4

Prednisone and Aspirin

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

2 5

TOL-3021

TTolerion, Inc.

Phase 2

3 6

SCRI-CAR19v3

SSeattle Children's Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2041

Phase 1Recruiting

Autoimmunity

NCT06465147

Clinical

Trials by Indication[1]

Autoimmunity1 trial

REACT-01: Reversing Autoimmunity Through Cell Therapy

Recruiting·SSeattle Children's Hospital·Phase 1·NCT06465147·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCRI-CAR19v3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCRI-CAR19v3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCRI-CAR19v3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSeattle Children's Hospital

SCRI-CAR19v3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2041

Trials by Indication[1]

Autoimmunity1 trial

References

Drug Info

Quick Facts

Related News